Market Closed -
Xetra
09:06:01 02/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
41
EUR
|
+0.12%
|
|
+4.86%
|
-27.30%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
319
|
530
|
651.7
|
1,309
|
904.6
|
724.1
|
-
|
-
|
Enterprise Value (EV)
1 |
296.6
|
487.8
|
626.6
|
1,648
|
904.6
|
691.8
|
672.5
|
633.4
|
P/E ratio
|
-139
x
|
-98.4
x
|
-48.4
x
|
33.4
x
|
11.9
x
|
-39
x
|
-300
x
|
15.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
0.59%
|
-
|
Capitalization / Revenue
|
9.41
x
|
15.5
x
|
17.6
x
|
30.8
x
|
11.6
x
|
12.2
x
|
9.65
x
|
4.91
x
|
EV / Revenue
|
8.75
x
|
14.3
x
|
17
x
|
38.8
x
|
11.6
x
|
11.7
x
|
8.96
x
|
4.3
x
|
EV / EBITDA
|
-212
x
|
-101
x
|
-50.6
x
|
-104
x
|
596
x
|
-40.3
x
|
43.5
x
|
7.46
x
|
EV / FCF
|
-123
x
|
-86.1
x
|
-42.1
x
|
-36.1
x
|
-
|
-10.4
x
|
-31.2
x
|
19.7
x
|
FCF Yield
|
-0.81%
|
-1.16%
|
-2.38%
|
-2.77%
|
-
|
-9.57%
|
-3.21%
|
5.08%
|
Price to Book
|
6.62
x
|
8.57
x
|
11.6
x
|
3.67
x
|
-
|
1.24
x
|
1.26
x
|
1.14
x
|
Nbr of stocks (in thousands)
|
10,000
|
10,000
|
11,047
|
15,130
|
16,039
|
17,660
|
-
|
-
|
Reference price
2 |
31.90
|
53.00
|
59.00
|
86.50
|
56.40
|
41.00
|
41.00
|
41.00
|
Announcement Date
|
18/05/20
|
17/05/21
|
18/05/22
|
27/04/23
|
25/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
33.9
|
34.23
|
36.96
|
42.5
|
77.7
|
59.32
|
75.02
|
147.4
|
EBITDA
1 |
-1.4
|
-4.81
|
-12.39
|
-15.87
|
1.518
|
-17.18
|
15.48
|
84.95
|
EBIT
1 |
-2.3
|
-5.725
|
-13.33
|
-17.73
|
-0.369
|
-22.08
|
-3.6
|
57.68
|
Operating Margin
|
-6.78%
|
-16.73%
|
-36.07%
|
-41.72%
|
-0.47%
|
-37.21%
|
-4.8%
|
39.12%
|
Earnings before Tax (EBT)
1 |
-2.291
|
-5.923
|
-13.47
|
36.6
|
79.07
|
-10.08
|
3.675
|
75
|
Net income
1 |
-2.293
|
-5.926
|
-13.48
|
35.99
|
75.8
|
-15.97
|
0.325
|
57.02
|
Net margin
|
-6.76%
|
-17.31%
|
-36.46%
|
84.69%
|
97.55%
|
-26.91%
|
0.43%
|
38.68%
|
EPS
2 |
-0.2293
|
-0.5387
|
-1.218
|
2.590
|
4.720
|
-1.050
|
-0.1367
|
2.687
|
Free Cash Flow
1 |
-2.403
|
-5.662
|
-14.88
|
-45.64
|
-
|
-66.2
|
-21.58
|
32.2
|
FCF margin
|
-7.09%
|
-16.54%
|
-40.26%
|
-107.39%
|
-
|
-111.59%
|
-28.76%
|
21.84%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
37.9%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
56.47%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
0.2433
|
-
|
Announcement Date
|
18/05/20
|
17/05/21
|
18/05/22
|
27/04/23
|
25/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 S1
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
1.804
|
Net margin
|
-
|
EPS
2 |
0.1130
|
Dividend per Share
|
-
|
Announcement Date
|
30/08/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
339
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
22.4
|
42.2
|
25.2
|
-
|
-
|
32.3
|
51.5
|
90.7
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-21.36
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-2.4
|
-5.66
|
-14.9
|
-45.6
|
-
|
-66.2
|
-21.6
|
32.2
|
ROE (net income / shareholders' equity)
|
-5.63%
|
-10.2%
|
-21.7%
|
17.5%
|
-
|
-3.4%
|
-0.05%
|
9.55%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
4.820
|
6.190
|
5.070
|
23.60
|
-
|
33.10
|
32.60
|
36.10
|
Cash Flow per Share
2 |
-
|
-0.4600
|
-1.280
|
-1.380
|
-
|
-1.690
|
0.5000
|
3.630
|
Capex
1 |
0.92
|
0.56
|
0.7
|
26.8
|
-
|
37.1
|
44.7
|
47.1
|
Capex / Sales
|
2.72%
|
1.63%
|
1.9%
|
62.97%
|
-
|
62.58%
|
59.58%
|
31.95%
|
Announcement Date
|
18/05/20
|
17/05/21
|
18/05/22
|
27/04/23
|
25/04/24
|
-
|
-
|
-
|
Average target price
91.8
EUR Spread / Average Target +123.90% Consensus |
1st Jan change
|
Capi.
|
---|
| -27.30% | 772M | | +26.28% | 42.68B | | -3.99% | 42.4B | | +45.32% | 40.04B | | -6.20% | 28.31B | | +6.36% | 24.94B | | -21.47% | 18.96B | | +27.58% | 12.3B | | -2.75% | 11.95B | | -2.02% | 11.55B |
Other Biotechnology & Medical Research
|